These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33326722)

  • 1. Audio Interview: Covid-19 Vaccine Fundamentals.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Dec; 383(25):e146. PubMed ID: 33326722
    [No Abstract]   [Full Text] [Related]  

  • 2. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.
    Frishman WH
    Cardiol Rev; 2021 May-Jun 01; 29(3):109. PubMed ID: 33758124
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
    Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
    Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
    [No Abstract]   [Full Text] [Related]  

  • 4. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
    Spinelli FR; Conti F; Gadina M
    Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
    Rubin R
    JAMA; 2022 Jun; 327(23):2281. PubMed ID: 35727290
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
    Quek E; Tahir H; Kumar P; Hastings R; Jha R
    Br J Hosp Med (Lond); 2021 Mar; 82(3):1-9. PubMed ID: 33792391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
    Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
    Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EUA for baricitinib (Olumiant) for COVID-19.
    Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
    [No Abstract]   [Full Text] [Related]  

  • 9. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repigmentation of vitiligo with oral baricitinib.
    Mumford BP; Gibson A; Chong AH
    Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
    Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
    Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib: A chance to treat COVID-19?
    Lo Caputo S; Corso G; Clerici M; Santantonio TA
    J Med Virol; 2020 Nov; 92(11):2343-2344. PubMed ID: 32437019
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
    Nousari Y; Wu BC; Valenzuela G
    Clin Exp Dermatol; 2021 Oct; 46(7):1330-1332. PubMed ID: 33914946
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic.
    Akiyama S; Yamada A; Sakuraba A
    J Med Virol; 2021 Feb; 93(2):714-716. PubMed ID: 32949157
    [No Abstract]   [Full Text] [Related]  

  • 15. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
    Praveen D; Puvvada RC; M VA
    Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
    Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
    Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
    [No Abstract]   [Full Text] [Related]  

  • 17. Audio Interview: A Look at Covid-19 Prevention and Care in 2020.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Dec; 383(27):e147. PubMed ID: 33382936
    [No Abstract]   [Full Text] [Related]  

  • 18. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.
    Alunno A; Najm A; Machado PM; Bertheussen H; Burmester GR; Carubbi F; De Marco G; Giacomelli R; Hermine O; Isaacs JD; Koné-Paut I; Magro-Checa C; McInnes IB; Meroni PL; Quartuccio L; Ramanan AV; Ramos-Casals M; Rodríguez Carrio J; Schulze-Koops H; Stamm TA; Tas SW; Terrier B; McGonagle DG; Mariette X
    Ann Rheum Dis; 2022 Jan; 81(1):34-40. PubMed ID: 34620584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib in Alopecia Areata.
    Messenger A; Harries M
    N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.